1-9 of 9
Anthony R. Mato
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

Protein Profiles Predict Treatment Responses to the PI3K Inhibitor Umbralisib in Patients with Chronic Lymphocytic Leukemia

Yanping Yin, Haifeng Xu, Liye He, Jennifer R. Brown, Anthony R. Mato, Tero Aittokallio, Sigrid S. Skånland
Journal: Clinical Cancer Research
Clin Cancer Res OF1–OF13.
https://doi.org/10.1158/1078-0432.CCR-24-2911
Published: 15 April 2025
View articletitled, Protein Profiles Predict Treatment Responses to the PI3K Inhibitor Umbralisib in Patients with Chronic Lymphocytic Leukemia
Open the PDF for Protein Profiles Predict Treatment Responses to the PI3K Inhibitor Umbralisib in Patients with Chronic Lymphocytic Leukemia in another window
Includes: Supplementary data
Journal Articles

Functional Testing to Characterize and Stratify PI3K Inhibitor Responses in Chronic Lymphocytic Leukemia

Yanping Yin, Paschalis Athanasiadis, Linda Karlsen, Aleksandra Urban, Haifeng Xu, Ishwarya Murali, Stacey M. Fernandes, Alberto J. Arribas, Abdul K. Hilli, Kjetil Taskén, Francesco Bertoni, Anthony R. Mato, Emmanuel Normant, Jennifer R. Brown, Geir E. Tjønnfjord, Tero Aittokallio, Sigrid S. Skånland
Journal: Clinical Cancer Research
Clin Cancer Res (2022) 28 (20): 4444–4455.
https://doi.org/10.1158/1078-0432.CCR-22-1221
Published: 14 October 2022
View articletitled, Functional Testing to Characterize and Stratify PI3K Inhibitor Responses in Chronic Lymphocytic Leukemia
Open the PDF for Functional Testing to Characterize and Stratify PI3K Inhibitor Responses in Chronic Lymphocytic Leukemia in another window
Includes: Supplementary data
Journal Articles

Adding Umbralisib and Ublituximab (U2) to Ibrutinib in Patients with CLL: A Phase II Study of an MRD-Driven Approach

Lindsey E. Roeker, Tatyana A. Feldman, Jacob D. Soumerai, Victoria Falco, Gail Panton, Colleen Dorsey, Andrew D. Zelenetz, Lorenzo Falchi, Jae H. Park, David J. Straus, Camila Pena Velasquez, Sonia Lebowitz, Yehudit Fox, Kristen Battiato, Carissa Laudati, Meghan C. Thompson, Elizabeth McCarthy, Sabrina Kdiry, Rosalba Martignetti, Teja Turpuseema, Michelle Purdom, Dana Paskalis, Hari P. Miskin, Peter Sportelli, Lori A. Leslie, Anthony R. Mato
Journal: Clinical Cancer Research
Clin Cancer Res (2022) 28 (18): 3958–3964.
https://doi.org/10.1158/1078-0432.CCR-22-0964
Published: 15 September 2022
View articletitled, Adding Umbralisib and Ublituximab (U2) to Ibrutinib in Patients with CLL: A Phase II Study of an MRD-Driven Approach
Open the PDF for Adding Umbralisib and Ublituximab (U2) to Ibrutinib in Patients with CLL: A Phase II Study of an MRD-Driven Approach in another window
Includes: Supplementary data
Journal Articles

Recognizing Unmet Need in the Era of Targeted Therapy for CLL/SLL: “What's Past Is Prologue” (Shakespeare)

Anthony R. Mato, Matthew S. Davids, Jeff Sharman, Lindsey E. Roeker, Neil Kay, Arnon P. Kater, Kerry Rogers, Meghan C. Thompson, Joanna Rhodes, Andre Goy, Alan Skarbnik, Stephen J. Schuster, Constantine S. Tam, Toby A. Eyre, Susan O'Brien, Chadi Nabhan, Nicole Lamanna, Clare Sun, Mazyar Shadman, John M. Pagel, Chaitra Ujjani, Danielle Brander, Catherine C. Coombs, Nitin Jain, Chan Y. Cheah, Jennifer R. Brown, John F. Seymour, Jennifer A. Woyach
Journal: Clinical Cancer Research
Clin Cancer Res (2022) 28 (4): 603–608.
https://doi.org/10.1158/1078-0432.CCR-21-1237
Published: 15 February 2022
View articletitled, Recognizing Unmet Need in the Era of Targeted Therapy for CLL/SLL: “What's Past Is Prologue” (Shakespeare)
Open the PDF for Recognizing Unmet Need in the Era of Targeted Therapy for CLL/SLL: “What's Past Is Prologue” (Shakespeare) in another window
Journal Articles

BTK Inhibitors in Cancer Patients with COVID-19: “The Winner Will be the One Who Controls That Chaos” (Napoleon Bonaparte)

Elise A. Chong, Lindsey E. Roeker, Mazyar Shadman, Matthew S. Davids, Stephen J. Schuster, Anthony R. Mato
Journal: Clinical Cancer Research
Clin Cancer Res (2020) 26 (14): 3514–3516.
https://doi.org/10.1158/1078-0432.CCR-20-1427
Published: 15 July 2020
View articletitled, BTK Inhibitors in Cancer Patients with COVID-19: “The Winner Will be the One Who Controls That Chaos” (Napoleon Bonaparte)
Open the PDF for BTK Inhibitors in Cancer Patients with COVID-19: “The Winner Will be the One Who Controls That Chaos” (Napoleon Bonaparte) in another window
Journal Articles

Assessment of the Efficacy of Therapies Following Venetoclax Discontinuation in CLL Reveals BTK Inhibition as an Effective Strategy

Anthony R. Mato, Lindsey E. Roeker, Ryan Jacobs, Brian T. Hill, Nicole Lamanna, Danielle Brander, Mazyar Shadman, Chaitra S. Ujjani, Maryam Sarraf Yazdy, Guilherme Fleury Perini, Javier A. Pinilla-Ibarz, Jacqueline Barrientos, Alan P. Skarbnik, Pallawi Torka, Jeffrey J. Pu, John M. Pagel, Satyen Gohil, Bita Fakhri, Michael Choi, Catherine C. Coombs, Joanna Rhodes, Paul M. Barr, Craig A. Portell, Helen Parry, Christine A. Garcia, Kate J. Whitaker, Allison M. Winter, Andrea Sitlinger, Sirin Khajavian, Ariel F. Grajales-Cruz, Krista M. Isaac, Pratik Shah, Othman S. Akhtar, Rachael Pocock, Kentson Lam, Timothy J. Voorhees, Stephen J. Schuster, Thomas D. Rodgers, Christopher P. Fox, Nicolas Martinez-Calle, Talha Munir, Erica B. Bhavsar, Neil Bailey, Jason C. Lee, Hanna B. Weissbrot, Chadi Nabhan, Julie M. Goodfriend, Amber C. King, Andrew D. Zelenetz, Colleen Dorsey, Kayla Bigelow, Bruce D. Cheson, John N. Allan, Toby A. Eyre
Journal: Clinical Cancer Research
Clin Cancer Res (2020) 26 (14): 3589–3596.
https://doi.org/10.1158/1078-0432.CCR-19-3815
Published: 15 July 2020
View articletitled, Assessment of the Efficacy of Therapies Following Venetoclax Discontinuation in CLL Reveals BTK Inhibition as an Effective Strategy
Open the PDF for Assessment of the Efficacy of Therapies Following Venetoclax Discontinuation in CLL Reveals BTK Inhibition as an Effective Strategy in another window
Includes: Supplementary data
Journal Articles

Tumor Lysis, Adverse Events, and Dose Adjustments in 297 Venetoclax-Treated CLL Patients in Routine Clinical Practice

Lindsey E. Roeker, Christopher P. Fox, Toby A. Eyre, Danielle M. Brander, John N. Allan, Stephen J. Schuster, Chadi Nabhan, Brian T. Hill, Nirav N. Shah, Frederick Lansigan, Maryam Yazdy, Bruce D. Cheson, Nicole Lamanna, Arun K. Singavi, Catherine C. Coombs, Paul M. Barr, Alan P. Skarbnik, Mazyar Shadman, Chaitra S. Ujjani, Hande H. Tuncer, Allison M. Winter, Joanna Rhodes, Colleen Dorsey, Hannah Morse, Charlene Kabel, John M. Pagel, Annalynn M. Williams, Ryan Jacobs, Andre Goy, Sivraj Muralikrishnan, Laurie Pearson, Andrea Sitlinger, Neil Bailey, Anna Schuh, Amy A. Kirkwood, Anthony R. Mato
Journal: Clinical Cancer Research
Clin Cancer Res (2019) 25 (14): 4264–4270.
https://doi.org/10.1158/1078-0432.CCR-19-0361
Published: 15 July 2019
View articletitled, Tumor Lysis, Adverse Events, and Dose Adjustments in 297 Venetoclax-Treated CLL Patients in Routine Clinical Practice
Open the PDF for Tumor Lysis, Adverse Events, and Dose Adjustments in 297 Venetoclax-Treated CLL Patients in Routine Clinical Practice in another window
Includes: Supplementary data
Journal Articles

Combination of Lenalidomide and Rituximab Overcomes Rituximab Resistance in Patients with Indolent B-cell and Mantle Cell Lymphomas

Elise A. Chong, Tahamtan Ahmadi, Nicole A. Aqui, Jakub Svoboda, Sunita D. Nasta, Anthony R. Mato, Kristy M. Walsh, Stephen J. Schuster
Journal: Clinical Cancer Research
Series: Author Choice
Clin Cancer Res (2015) 21 (8): 1835–1842.
https://doi.org/10.1158/1078-0432.CCR-14-2221
Published: 14 April 2015
View articletitled, Combination of Lenalidomide and Rituximab Overcomes Rituximab Resistance in Patients with Indolent B-cell and Mantle Cell Lymphomas
Open the PDF for Combination of Lenalidomide and Rituximab Overcomes Rituximab Resistance in Patients with Indolent B-cell and Mantle Cell Lymphomas in another window
Includes: Supplementary data
Journal Articles

A Phase I Study of Bexarotene, a Retinoic X Receptor Agonist, in Non-M3 Acute Myeloid Leukemia

Donald E. Tsai, Selina M. Luger, Charalambos Andreadis, Dan T. Vogl, Allison Kemner, Melissa Potuzak, Ami Goradia, Alison W. Loren, Alexander E. Perl, Stephen J. Schuster, David L. Porter, Edward A. Stadtmauer, Steven C. Goldstein, James E. Thompson, Cezary Swider, Adam Bagg, Anthony R. Mato, Martin Carroll
Journal: Clinical Cancer Research
Clin Cancer Res (2008) 14 (17): 5619–5625.
https://doi.org/10.1158/1078-0432.CCR-07-5185
Published: 02 September 2008
View articletitled, A Phase I Study of Bexarotene, a Retinoic X Receptor Agonist, in Non-M3 Acute Myeloid Leukemia
Open the PDF for A Phase I Study of Bexarotene, a Retinoic X Receptor Agonist, in Non-M3 Acute Myeloid Leukemia in another window
Includes: Supplementary data